Alpine Immune Sciences (ALPN) News Today → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free ALPN Stock Alerts $64.56 -0.06 (-0.09%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPNbusinesswire.com - April 26 at 4:13 PMAlpine Immune Sciences, Inc. (ALPN)finance.yahoo.com - April 23 at 7:45 AMAlpine Immune Sciences (NASDAQ:ALPN) Sets New 1-Year High at $64.58marketbeat.com - April 22 at 7:38 PMAlpine Immune Sciences (NASDAQ:ALPN) Sees Unusually-High Trading Volumeamericanbankingnews.com - April 21 at 3:04 AMAlpine Immune Sciences, Inc. (NASDAQ:ALPN) Given Average Recommendation of "Hold" by Analystsamericanbankingnews.com - April 21 at 2:12 AMAlpine Immune Sciences (NASDAQ:ALPN) Sees Large Volume Increasemarketbeat.com - April 19 at 11:58 AMTD Cowen Downgrades Alpine Immune Sciences (ALPN)msn.com - April 18 at 7:07 PMINVESTIGATION: The M&A Class Action Firm Announces an Investigation of Alpine Immune Sciences, Inc. - ALPNprnewswire.com - April 17 at 7:50 PMAlpine Immune Sciences (ALPN) Price Target Increased by 36.91% to 63.24msn.com - April 17 at 8:23 AMAlpine Immune Sciences (NASDAQ:ALPN) Receives Hold Rating from TD Cowenamericanbankingnews.com - April 17 at 4:20 AMAlpine Immune Sciences, Inc. (NASDAQ:ALPN) Short Interest Updateamericanbankingnews.com - April 17 at 3:44 AMAlpine Immune Sciences (NASDAQ:ALPN) Given "Hold" Rating at TD Cowenmarketbeat.com - April 16 at 8:19 AMCan You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?investorplace.com - April 15 at 3:43 PMAlpine Immune Sciences, Inc. (NASDAQ:ALPN) Shares Bought by Vanguard Group Inc.marketbeat.com - April 15 at 4:15 AMAlpine Immune Sciences (NASDAQ:ALPN) Downgraded by Leerink Partnrs to Market Performmarketbeat.com - April 13 at 7:56 AMCould This Stock Be the Next Biotech Buyout?fool.com - April 13 at 5:29 AMSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Alpine Immune Sciences, Inc. Buyoutstockhouse.com - April 12 at 5:44 PMALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPNbusinesswire.com - April 12 at 5:17 PMAlpine Immune Sciences' (ALPN) "Market Perform" Rating Reaffirmed at SVB Leerinkmarketbeat.com - April 12 at 10:22 AMAlpine Immune Sciences (NASDAQ:ALPN) Downgraded by HC Wainwrightmarketbeat.com - April 12 at 5:59 AMThese Stocks Moved the Most Today: CarMax, Apple, Fastenal, Rivian, Alpine Immune, Nike, Robinhood, Constellation Brands, and Morefinance.yahoo.com - April 11 at 5:53 PMVertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'seekingalpha.com - April 11 at 12:52 PMVertex Pharmaceuticals to Buy Alpine Immune in $4.9B Dealbarrons.com - April 11 at 10:46 AMAlpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy Itinvestors.com - April 11 at 10:36 AMThe $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Todayinvestorplace.com - April 11 at 9:47 AMAlpine Immune Sciences' (ALPN) "Neutral" Rating Reaffirmed at Wedbushmarketbeat.com - April 11 at 8:31 AMAlpine Immune Sciences soars on $4.9bn Vertex takeoverproactiveinvestors.com - April 11 at 7:16 AMVertex Stock in Focus After Deal to Buy Alpine Immune For $4.9B—Key Level to Watchinvestopedia.com - April 10 at 10:45 PMShareholder Alert: Ademi LLP investigates whether Alpine Immune Sciences, Inc. has obtained a Fair Price in its transaction with Vertexprnewswire.com - April 10 at 9:50 PMALPN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alpine Immune Sciences, Inc. Is Fair to Shareholdersbusinesswire.com - April 10 at 8:08 PMVertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Dealinvestors.com - April 10 at 4:45 PMVertex Pharmaceuticals to buy Alpine Immune Sciences for $4.9 blnreuters.com - April 10 at 4:20 PMmarketbeat.com - April 10 at 4:16 PMAlpine Immune Is Weighing Options After Takeover Interestbloomberg.com - April 10 at 4:15 PMWhy Is Kidney Disease-Focused Alpine Immune Sciences Stock Trading Higher On Wednesday?benzinga.com - April 10 at 4:15 PMAlpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathybusinesswire.com - April 10 at 4:15 PMVertex Enters Into Agreement to Acquire Alpine Immune Sciencesbusinesswire.com - April 10 at 4:01 PMVertex Enters Into Agreement to Acquire Alpine Immune Sciencesbusinesswire.com - April 10 at 4:01 PMAlpine Immune Sciences (NASDAQ:ALPN) Sets New 12-Month High at $45.44marketbeat.com - April 10 at 3:24 PMmarketbeat.com - April 10 at 12:38 PMNavigating 8 Analyst Ratings For Alpine Immune Sciencesmarkets.businessinsider.com - April 9 at 12:26 PMGuggenheim Begins Coverage on Alpine Immune Sciences (NASDAQ:ALPN)marketbeat.com - April 9 at 8:24 AMAlpine Immune Sciences (NASDAQ:ALPN) Trading Up 6.8%marketbeat.com - April 8 at 11:38 AMAlpine Immune Sciences (NASDAQ:ALPN) Shares Down 5.6% marketbeat.com - April 3 at 4:50 PMAlpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024finance.yahoo.com - April 1 at 5:21 PMAlpine Immune Sciences (NASDAQ:ALPN) Shares Up 6.3%marketbeat.com - March 21 at 5:42 PMAlpine Immune Sciences, Inc.: Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024finanznachrichten.de - March 21 at 9:23 AMBuy Rating Affirmed for Alpine Immune Sciences Amid Positive Povetacicept Trials and Strong Clinical Outlookmarkets.businessinsider.com - March 21 at 9:23 AMBrokers Offer Predictions for Alpine Immune Sciences, Inc.'s Q3 2024 Earnings (NASDAQ:ALPN)marketbeat.com - March 21 at 7:45 AMAlpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024businesswire.com - March 21 at 7:45 AM Get Alpine Immune Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ALPN and its competitors with MarketBeat's FREE daily newsletter. Email Address The Next Step of Their Control Is Here … (Ad)Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you. 4 simple steps to protect your privacy and money before it’s too late. ALPN Media Mentions By Week ALPN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALPN News Sentiment▼1.010.32▲Average Medical News Sentiment ALPN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALPN Articles This Week▼63▲ALPN Articles Average Week Get Alpine Immune Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ALPN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: NUVL News PRGO News ALKS News BBIO News OGN News INSM News MDGL News CBAY News BHVN News RARE News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALPN) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alpine Immune Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
